Aktuelle Bewertung von Chloroquin bei COVID-19

Die Datenlage rund um die Anwendung von Chloroquin und Hydroxychloroquin bei der Behandlung von COVID-19 ist widersprüchlich. In Folgendem soll deshalb der aktuelle wissenschaftliche Stand der Antimalariamedikamente abgebildet werden.

Liebe Leserin, lieber Leser,

der Inhalt dieses Artikels ist nur für medizinische Fachkreise zugelassen. Wenn Sie zu diesen Fachkreisen gehören, melden Sie sich bitte auf unserer Seite an. Sie werden dann automatisch auf die gewünschte Seite weitergeleitet.

Registrierung Anmeldung Vorteile

Autor:

Dr. Isabelle Viktoria Maucher (Apothekerin)

Stand:

18.04.2020

Quelle:

Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet. Respiratory medicine 2020.
Simonis FD, Serpa Neto A, Binnekade JM, Braber A, Bruin KCM, Determann RM et al. Effect of a Low vs Intermediate Tidal Volume Strategy on Ventilator-Free Days in Intensive Care Unit Patients Without ARDS: A Randomized Clinical Trial. JAMA 2018;320:1872–80.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research 2020;30:269–71.
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery 2020;6:16.
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases 2020.
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of critical care 2020.
[Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends 2020.
Gautret P, Lagier J-C, Parola P, van Hoang T, Meddeb L, Mailhe M et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents 2020:105949.
[Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive care medicine 2020:1–34.
The Lancet Respiratory Medicine. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base; Published: 2020. Available from: URL: https://doi.org/10.1016/S2213-2600(20)30172-7.
Philippe Gautret, Lagier J. C., Parola P et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study; 2020. Available from: URL: https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf.
medRXiv. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.; medRxiv. 2020; (published online March 31.) (preprint). Available from: URL: DOI: 10.1101/2020.03.22.20040758.
Molina JM, Delaugerre C, Goff JL, Mela-Lima B, Ponscarme D, Goldwirt L et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020:30085–8.